DRSC e. V. • Zimmerstr. 30 • 10969 Berlin

Telefon +49 (0)30 206412-12

Telefax

+49 (0)30 206412-15

E-Mail

info@drsc.de

EFRAG Françoise Flores 35 Square de Meeûs B-1000 Brussels Belgique

Berlin, 2 September 2013

Dear Françoise,

EFRAG'S DRAFT ENDORSEMENT ADVICE AND EFFECTS STUDY REPORT ON IFRIC Interpretation 21 – *Levies*

On behalf of the German IFRS Committee I am writing to comment on EFRAG's Assessment of IFRIC 21 *Levies*.

We agree with the views set out in the assessment. As a national standard-setter we are not in a position to answer the questions regarding the costs that will arise for preparers and for users to implement the interpretation. We therefore sent your assessment-form to the DAX30 entities and got feedback from two companies, which indicated that they agree with EFRAG's assessment.

As attachments to this letter you will find our comments to the above mentioned assessment as well as those received from the DAX30 entities.

If you have any further questions, please do not hesitate to contact me.

Yours sincerely,

Liesel Knorr

President



DRAFT ENDORSEMENT ADVICE AND EFFECTS STUDY REPORT ON IFRIC INTERPRETATION 21 LEVIES

INVITATION TO COMMENT ON EFRAG'S ASSESSMENTS

Comments should be sent to <u>commentletters@efrag.org</u> by 2 September 2013

EFRAG has been asked by the European Commission to provide it with advice and supporting material on IFRIC Interpretation 21 *Levies* ('IFRIC 21' or 'the Interpretation'). In order to do that, EFRAG has been carrying out an assessment of IFRIC 21 against the technical criteria for endorsement set out in Regulation (EC) No 1606/2002 and has also been assessing the costs and benefits that would arise from its implementation in the European Union (the EU) and European Economic Area.

A summary of IFRIC 21 is set out in Appendix 1.

1

Disease provide the following details about volume of

Before finalising its two assessments, EFRAG would welcome your views on the issues set out below. Please note that all responses received will be placed on the public record, unless the respondent requests confidentiality. In the interest of transparency EFRAG will wish to discuss the responses it receives in a public meeting, so we would prefer to be able to publish all the responses received.

EFRAG's initial assessments summarised in this questionnaire will be amended to reflect EFRAG's decisions on Appendix 2 and 3.

Pleas	se provide the following details about yoursell:
(a)	Your name or, if you are responding on behalf of an organisation or company its name:
	Liesel Knorr, ASCG (Accounting Standards Committee
	of Germany)
(b)	Are you a:
	☐ Preparer ☐ User ☒ Other (please specify)
	National Standard Setter
(c)	Please provide a short description of your activity:
	see above (b)

(d) Country where you are located: (e) Contact details including e-mail address: knorr@drsc.de 2 EFRAG's initial assessment of IFRIC 21 is that it meets the technical criteria for endorsement. In other words, it is not contrary to the principle of true and fair view and it meets the criteria of understandability, relevance, reliability and comparability. EFRAG's reasoning is set out in Appendix 2. Do you agree with this assessment? ⊠ Yes ☐ No If you do not, please explain why you do not agree and what you believe the implications of this should be for EFRAG's endorsement advice. Are there any issues that are not mentioned in Appendix 2 that you believe EFRAG should take into account in its technical evaluation of IFRIC 21? If there are, what are those issues and why do you believe they are relevant to the evaluation? none

Draft Endorsement Advice on IFRIC 21 Levies

3 EFRAG is also assessing the costs that are likely to arise for preparers and for users on implementation of IFRIC 21 in the EU and European Economic Area, both in year one and in subsequent years. Some initial work has been carried out, and the responses to this Invitation to Comment will be used to complete the assessment.

The results of the initial assessment of costs are set out in paragraphs 2 to 7 of Appendix 3. To summarise, EFRAG's initial assessment is that is there is no significant cost for the adoption of IFRIC 21 and that its benefit outweighs its cost.

	ith this assessment?
Yes	□ No
	lease explain why you do not and (if possible) explain broadly wha costs involved will be?
We as a Nat	onal Standard Letter are not in a position to
comment on	this issue. Both our constituents responding
to this sur	vey agree with EFRAG's assessment.
FRIC 21. The post of Appendix 3. Denefit from IFI	RAG is assessing the benefits that are likely to be derived from esults of the initial assessment of benefits are set out in paragraph 7 To summarise, EFRAG's initial assessment is that users are likely to RIC 21, as it is likely to reduce the diversity of accounting in practice comparability and consistency of the information provided to all
Do you agree w	ith this assessment?
☐ Yes	□ No
	agree with this assessment, please provide your arguments and should affect EFRAG's endorsement advice?
We as a Nat	onal Standard Letter are not in a position to
comment on	this issue. Both our constituents responding
to this sur	vey agree with EFRAG's assessment.
IFRIC 21 in the	assessment is that the benefits to be derived from implementing EU and the European Economic Area as described in paragraph 4 to outweigh the costs involved as described in paragraph 3 above.
Do you agree w	ith this assessment?
⊠ Yes	□ No
	agree with this assessment, please provide your arguments and s should affect EFRAG's endorsement advice?

reaching a decision as to what endorsement advice it should give the European Commission on IFRIC 21.

none		
•	agree, please provide s endorsement advice	your arguments and indicate how this should?
⊠ Yes	☐ No	
Do you agree t	that there are no other	tactors?



DRAFT ENDORSEMENT ADVICE AND EFFECTS STUDY REPORT ON IFRIC INTERPRETATION 21 LEVIES

INVITATION TO COMMENT ON EFRAG'S ASSESSMENTS

Comments should be sent to <u>commentletters@efrag.org</u> by 2 September 2013

EFRAG has been asked by the European Commission to provide it with advice and supporting material on IFRIC Interpretation 21 *Levies* ('IFRIC 21' or 'the Interpretation'). In order to do that, EFRAG has been carrying out an assessment of IFRIC 21 against the technical criteria for endorsement set out in Regulation (EC) No 1606/2002 and has also been assessing the costs and benefits that would arise from its implementation in the European Union (the EU) and European Economic Area.

A summary of IFRIC 21 is set out in Appendix 1.

Diagon provide the following details chart very self-

1

Before finalising its two assessments, EFRAG would welcome your views on the issues set out below. Please note that all responses received will be placed on the public record, unless the respondent requests confidentiality. In the interest of transparency EFRAG will wish to discuss the responses it receives in a public meeting, so we would prefer to be able to publish all the responses received.

EFRAG's initial assessments summarised in this questionnaire will be amended to reflect EFRAG's decisions on Appendix 2 and 3.

riea	se provide the following details about yoursell.
(a)	Your name or, if you are responding on behalf of an organisation or company, its name:
	Dr. Martin Schloemer, Bayer AG
(b)	Are you a:
	□ Preparer □ User □ Other (please specify)
(c)	Please provide a short description of your activity:
	Healthcare, MaterialScience, CropScience

(d) Country where you are located: Germany (e) Contact details including e-mail address: Martin.schloemer@bayer.com 2 EFRAG's initial assessment of IFRIC 21 is that it meets the technical criteria for endorsement. In other words, it is not contrary to the principle of true and fair view and it meets the criteria of understandability, relevance, reliability and comparability. EFRAG's reasoning is set out in Appendix 2. Do you agree with this assessment? ⊠ Yes ☐ No If you do not, please explain why you do not agree and what you believe the implications of this should be for EFRAG's endorsement advice. Are there any issues that are not mentioned in Appendix 2 that you believe EFRAG should take into account in its technical evaluation of IFRIC 21? If there are, what are those issues and why do you believe they are relevant to the evaluation?

Draft Endorsement Advice on IFRIC 21 Levies

3 EFRAG is also assessing the costs that are likely to arise for preparers and for users on implementation of IFRIC 21 in the EU and European Economic Area, both in year one and in subsequent years. Some initial work has been carried out, and the responses to this Invitation to Comment will be used to complete the assessment.

The results of the initial assessment of costs are set out in paragraphs 2 to 7 of Appendix 3. To summarise, EFRAG's initial assessment is that is there is no significant cost for the adoption of IFRIC 21 and that its benefit outweighs its cost.

Do you agree	e with this assessment?
⊠ Yes	□ No
•	, please explain why you do not and (if possible) explain broadly wha ne costs involved will be?
IFRIC 21. Th of Appendix 3 benefit from 1	EFRAG is assessing the benefits that are likely to be derived from e results of the initial assessment of benefits are set out in paragraph is. To summarise, EFRAG's initial assessment is that users are likely to IFRIC 21, as it is likely to reduce the diversity of accounting in practice ing comparability and consistency of the information provided to a
Do you agree	e with this assessment?
⊠ Yes	□ No
IFRIC 21 in t	ial assessment is that the benefits to be derived from implementing the EU and the European Economic Area as described in paragraph all to outweigh the costs involved as described in paragraph 3 above.
Do you agree	e with this assessment?
⊠ Yes	□ No
•	nt agree with this assessment, please provide your arguments and this should affect EFRAG's endorsement advice?
	ot aware of any other factors that should be taken into account i

Do you agree that	at there are no othe	er factors?
⊠ Yes	☐ No	
	ree, please providendorsement advice	e your arguments and indicate how this shoulde?



DRAFT ENDORSEMENT ADVICE AND EFFECTS STUDY REPORT ON IFRIC INTERPRETATION 21 LEVIES

INVITATION TO COMMENT ON EFRAG'S ASSESSMENTS

Comments should be sent to <u>commentletters@efrag.org</u> by 2 September 2013

EFRAG has been asked by the European Commission to provide it with advice and supporting material on IFRIC Interpretation 21 *Levies* ('IFRIC 21' or 'the Interpretation'). In order to do that, EFRAG has been carrying out an assessment of IFRIC 21 against the technical criteria for endorsement set out in Regulation (EC) No 1606/2002 and has also been assessing the costs and benefits that would arise from its implementation in the European Union (the EU) and European Economic Area.

A summary of IFRIC 21 is set out in Appendix 1.

1

Disease provide the following details about volume of

Before finalising its two assessments, EFRAG would welcome your views on the issues set out below. Please note that all responses received will be placed on the public record, unless the respondent requests confidentiality. In the interest of transparency EFRAG will wish to discuss the responses it receives in a public meeting, so we would prefer to be able to publish all the responses received.

EFRAG's initial assessments summarised in this questionnaire will be amended to reflect EFRAG's decisions on Appendix 2 and 3.

Piea	se provide the following details about yoursell:
(a)	Your name or, if you are responding on behalf of an organisation or company, its name:
	Linde AG
(b)	Are you a:
	X Preparer User Other (please specify)
(c)	Please provide a short description of your activity:
	Gases / Chemistry / Engineering

Draft Endorsement Advice on IFRIC 21 Levies (d) Country where you are located: Germany / globally (e) Contact details including e-mail address: Dr. Hans-Dieter Fladung Klosterhofstraße 1, 80331 München Hans-dieter.fladung@linde.com

2 EFRAG's initial assessment of IFRIC 21 is that it meets the technical criteria for endorsement. In other words, it is not contrary to the principle of true and fair view and it meets the criteria of understandability, relevance, reliability and comparability. EFRAG's reasoning is set out in Appendix 2.

□ No

(a)	Do you agre	e with this	assessment?
-----	-------------	-------------	-------------

X Yes

(b)

7				
If you do not, plea implications of this	. , , ,	•	•	believe the
Are there any issu EFRAG should tal there are, what are the evaluation?	ke into account i	in its technical	evaluation of IF	RIC 21? I

3 EFRAG is also assessing the costs that are likely to arise for preparers and for users on implementation of IFRIC 21 in the EU and European Economic Area, both in year one and in subsequent years. Some initial work has been carried out, and the responses to this Invitation to Comment will be used to complete the assessment.

The results of the initial assessment of costs are set out in paragraphs 2 to 7 of Appendix 3. To summarise, EFRAG's initial assessment is that is there is no significant cost for the adoption of IFRIC 21 and that its benefit outweighs its cost.

If you do no	t, please explain why you do not and (if possible) explain broadly
you believe	the costs involved will be?
_	
IFRIC 21. To of Appendix benefit from	EFRAG is assessing the benefits that are likely to be derived ne results of the initial assessment of benefits are set out in paragra 3. To summarise, EFRAG's initial assessment is that users are like IFRIC 21, as it is likely to reduce the diversity of accounting in pracing comparability and consistency of the information provided to s.
Do you agre	e with this assessment?
X Yes	□ No
7. 100	
	this should affect EFRAG's endorsement advice?
IFRIC 21 in	itial assessment is that the benefits to be derived from implement the EU and the European Economic Area as described in paragra kely to outweigh the costs involved as described in paragraph 3 abo
Do you agre	e with this assessment?
X Yes	□ No
	ot agree with this assessment, please provide your arguments this should affect EFRAG's endorsement advice?

Do you agree that the	ere are no other fac	tors?		
X Yes	□ No			
If you do not agree, affect EFRAG's endo		ur arguments an	d indicate ho	w this should